Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography
- Conditions
- InfertilityPain
- Interventions
- Drug: Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)Drug: PlaceboProcedure: Hysterosalpingography (HSG)
- Registration Number
- NCT00893412
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
This study evaluates the analgetic effects of the fast-release orodispersible tramadol tablet.
Tramadol acts through a weak affinity for μ receptors and secondly by inhibiting noradrenaline and serotonin neuronal reuptake. It has been used since the 1970s by over 50 million people for the treatment of acute and chronic pain. The orodispersible Tramadol tablet is a new galenic form and is available on the Belgian market for the last three years. Pregastric absorption leads to a quicker onset of action.
So far, evidence shows that pain during and immediately after the Hysterosalpingography (HSG) procedure is only significantly reduced by IV opioid analgesia. This study evaluates the analgetic potential of an orodispersible opioid tablet. This tablet disintegrates rapidly (in around 20-30 seconds) and may be taken without water. Its abuse potential is very low and its respiratory depressant effect is negligible.
- Detailed Description
Four arm prospective randomized double blinded trial
Patients that need a HSG as part of their diagnostic work-up and are eligible for randomization are counseled about possible participation. After signing the informed consent patients will be randomized in one of the following four groups:
Group 1: Fast-release Orodispersible Tramadol Tablet + metal cannula Group 2: Placebo + metal cannula Group 3: Fast-release Orodispersible Tramadol Tablet + balloon catheter Group 4: Placebo + balloon catheter
Tablets are administered 30 min before the procedure
Primary Endpoint:
* VAS at the six different assessment points
Secondary Endpoint
* adverse effects and complications such as: nausea, vomiting, constipation, drowsiness, respiratory depression, hypotension, allergic reaction and infection
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 128
- > 18 and < 45 years
- Written informed consent
-
Contra-indication to tramadol, morphine or to other opioids
- Concomitant use of MAO inhibitors or use less than 2 weeks prior to procedure
- Use of any other CNS-acting drug
-
Contra-indication to radio-contrast medium (allergy)
-
Patient already taking analgetics
-
History of cervical stenosis
-
Presence of pelvic inflammatory disease or any other condition causing pelvic pain
-
Clinical and/or laboratory evidence of any major disease
-
Pregnant or lactating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo + Metal cannula Placebo Placebo + Metal cannula Tramadol + Metal cannula Fast-release Orodispersible Tramadol Tablet (Tradonal odis®) Fast-release Orodispersible Tramadol Tablet + Metal cannula Tramadol + Metal cannula Hysterosalpingography (HSG) Fast-release Orodispersible Tramadol Tablet + Metal cannula Placebo + Metal cannula Hysterosalpingography (HSG) Placebo + Metal cannula Tramadol + Balloon Fast-release Orodispersible Tramadol Tablet (Tradonal odis®) Fast-release Orodispersible Tramadol Tablet + balloon catheter Tramadol + Balloon Hysterosalpingography (HSG) Fast-release Orodispersible Tramadol Tablet + balloon catheter Placebo + Balloon Hysterosalpingography (HSG) Placebo + balloon catheter Placebo + Balloon Placebo Placebo + balloon catheter
- Primary Outcome Measures
Name Time Method VAS at the six different assessment points 24 hours
- Secondary Outcome Measures
Name Time Method Adverse effects and complications 24 hours
Trial Locations
- Locations (1)
UZ Brussel
🇧🇪Brussels, Belgium